Norethandrolone also reduced basal serum insulin levels. Norethandrolone seems appropriate for underweight patients and D-thyroxine for overweight patients, but side effects are more frequent than in nonuraemic patients.
Summary
Lowering of lipids in patients with chronic renal failure is advantageous but cannot be done by calorie restriction. In a controlled study the anabolic steroid norethandrolone (Nilevar) was found to lower triglycerides by 50%, while D-thyroxine (Choloxin) lowered the cholesterol by 25 %. Both drugs increased the activity of lipoprotein lipase in spite of uraemic inhibition.
Norethandrolone also reduced basal serum insulin levels. Norethandrolone seems appropriate for underweight patients and D-thyroxine for overweight patients, but side effects are more frequent than in nonuraemic patients.
introduction Patients with chronic renal failure tend to have high levels of serum triglyceride (Bagdade, 1970) and sometimes of cholesterol (Bagdade, Porte and Bierman, 1968; Brons, Christensen and Horder, 1972) . Increased triglyceride may depend in part on increased synthesis on account of the hyperinsulinism of chronic renal failure (Spitz et al., 1970) (Bierman, 1970) , in part on an increased contribution of carbohydrate to their total calorie intake (Gutman et al., 1973) , and in part on uraemic inhibition of the enzyme lipoprotein lipase (Boyer and Scheig, 1970) . Figure 1 is designed to explain these relationships. Now the implication is that chronic renal failure patients might be at risk from accelerated development of atherosclerosis because of their hyperlipaemia, which is incidentally not corrected by dialysis (Bagdade et al., 1968; Roodvoets et al., 1967) . Accelerated atherosclerosis is a feature of nephrotic patients (Berlyne and Mallick, 1969 importance when life is to be prolonged by dialysis with a view to renal transplantation. Rotter and Roettger (1973) The effects of therapeutic agents on lipid metabolism in chronic renal failure patients are largely unexplored. There is some impression that agents might not be effective (David et al., 1972) . In other hyperlipidaemic patients D-thyroxine (Choloxin) is known to lower the cholesterol (Schneeberg et al., 1962; Hollister and Arans, 1962) . Triglyceride levels are often lowered by androgens (Furman et al., 1968) , which may more conveniently be given as anabolic steroids, among which the agent oxandrolone (hydroxy-methyl-oxa-androstanone) is known to reduce carbohydrate induced hypertriglyceridaemia (Sachs and Wolfman, 1968) .
We have conducted a study of lipids in the serum of non-nephrotic chronic renal failure patients to examine first the effect of the anabolic steroid, norethandrolone (Nilevar) and then the actions of the cholesterol-lowering agent D-thyroxine (Choloxin).
Method
Fifteen patients selected for the stability of their non-nephrotic chronic renal failure volunteered to participate in the trial. Five had chronic pyelonephritis, three polycystic kidneys, three chronic glomerulonephritis and four chronic renal failure of unknown origin with hypertension. Only three patients had a urinary protein excretion exceeding 1 g/24 hr. The mean serum creatinine level was 4-6 mg% and creatinine clearances were in the range 5-60 ml/min, with a mean of 22 ml/min. At fortnightly intervals they attended after an overnight fast and had blood taken for serum triglycerides (Biochemical combination glycerokinase technique) and serum cholesterol (Modified Technicon N12), and additionally, serum free fatty acids (Duncombe, 1964) and serum post-heparin lipoprotein lipase activity (PHLA) by the method of Muir (1967) , after heparin 0-1 mg/kg given intravenously. Basal fasting plasma insulin levels were also measured using the Lepetit Insulin kit, which is a double antibody charcoal adsorption immunoassay. On one day each week using weighing scales they filled in a standard dietary questionnaire so that for that representative day their consumption of protein, fat and carbohydrate and, hence, their total calorie intake, could be ascertained. At each visit they were weighed and their skin-fold subcutaneous fat thickness was measured with calipers.
After a control period of 6 weeks, all patients started to take norethandrolone 20 mg/day and this was continued for 10 weeks, after which they entered another control period of 6 weeks. Thereafter under blind conditions they received either placebo or D-thyroxine at increasing dosage over a period of three weeks to 2 mg thrice daily, which was then maintained for another 7 weeks. In retrospect it turned out that eight patients received Choloxin and seven placebo. Finally, there was another control period of 4 weeks. At each visit there was a full examination and biochemical assessment. (Sodhi, Kudchodkar and Horlick, 1971) . The fall of the triglyceride-rich VLDL that it produces can be accompanied by some rise of the cholesterol-rich LDL (Miettinen, Penttila and Lampainen, 1972) . Clofibrate has been used in nephrotic patients but it is recommended that in uraemia blood levels should be estimated as side effects are easily produced. Many androgenicanabolic steroids lower chylomicrons, a-lipoproteins and pre-P lipoprotein triglycerides in, for example, patients with types III, IV and V hyperlipoproteinaemia. The best known are norethindrone acetate (Sigler and Issekutz, 1967) and oxandralone (Sachs and Wolfman, 1968) . Oxandralone also has a liability to raise the levels of LDL (Sachs, Danielson and Weston, 1956; Glueck, 1971) , and all these compounds alter serum proteins so that there is an elevation of protein-bound carbohydrate (Sachs et al., 1956) in the a and P globulins.
Results and comment
Our results show that norethandrolone has a triglyceride-lowering effect in uraemic patients that is appreciable. An effect on the liver synthesis of lipoproteins has to be assumed. Solyom (1972) has recently suggested that the androgens reduce the synthesis of the apoprotein moiety of the lipoprotein molecule. However, in addition we have noted that norethandrolone increases the activity of PHLA, even in uraemic patients in whom serum inhibitors of PHLA are known to occur (Boyer and Sheig, 1970) . Indeed it is already known that oxandralone and norethindrone acetate increase PHLA activity (Glueck, Swanson and Hutsell, 1970; Faergeman and Damgaard-Pedersen, 1973 ). Its use in uraemic patients can therefore be recommended for its triglyceride-lowering effect, but clearly attention must be paid to the possible side effects and the possibility of a cumulative action, as was apparent in these patients by the continued action for at least 4 weeks after withdrawal. It seems that the biological halflife of the drug is longer than circulating blood levels and so thereapeutic effect is not related to dosage. Further studymay well show that a 10mg dose would be sufficient in chronic renal patients.
D-Thyroxine was found in uraemic patients to lower the cholesterol, and the triglyceride. It also produced weight loss, and this was certainly beneficial for overweight patients. In fact our patients did not receive propranolol concurrent with Choloxin but this is recommended in patients who are liable to latent ischaemic heart disease (Krikler, Lefevre and Lewis, 1971) . The action of D-thyroxine is thought to be due to an increased catabolism of cholesterol to bile acids that are then lost in the faeces (Best and Duncan, 1960; Miettinen, 1968) . In our patients it also increased PHLA activity: this is a new finding. Indeed a reduction of PHLA has been found in thyrotoxicosis and this is explained by an increased turnover of the enzyme (Tulloch, Lewis and Russell Fraser, 1973) .
The observation that norethandrolone lowered basal insulin levels is important: studies are now required to see whether glucose-stimulated insulin secretion is also lowered by this drug. The finding must be compared with the recent report that clofibrate can restore normal triglyceride-insulin relations (Eaton and Nye, 1973) . Lowering of insulin secretion by diazoxide results in reduction of serum triglyceride levels (Eaton and Nye, 1973) .
In conclusion it appears that elevated triglyceride 
